There are currently 465 clinical trials in Kansas City, Kansas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Kansas Medical Center, University of Kansas Cancer Center, Kansas University Medical Center and Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
NCT05865886
Recruiting
This study is open to adults aged 18 years and older with cystic fibrosis bronchiectasis. The purpose of this study is to find out whether a medicine called BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis. Participants are put randomly into 2 groups. One group takes BI 1291583 tablets and the other group takes placebo tablets. Placebo tablets look like BI 1291583 tablets but do not contain any medicine. Participants in both groups take 1 tablet once a day for 12 weeks. Par... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Cystic Fibrosis, Bronchiectasis
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: The University of Kansas Cancer Center,2000 Olathe Blvd, Kansas City, Kansas
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230
Recruiting
This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term. Participants take a low, medium, or high dose of BI... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Bronchiectasis
Register for Updates
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
NCT04071236
Recruiting
This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as radium-223 dichloride, may carry radiation directly to tumor cells and not harm norm... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Metastatic Malignant Neoplasm in the Lymph Nodes
Register for Updates
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
NCT04624490
Recruiting
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.
Gender:
All
Ages:
3 years and above
Trial Updated:
06/07/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Register for Updates
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
NCT06002828
Recruiting
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer sur... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Register for Updates
Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease
NCT05755711
Recruiting
Post-market, prospective, multi-center, single-arm observational study to generate real-world clinical evidence associated with coronary IVL in a population of female subjects with calcified coronary artery disease.
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Coronary Artery Disease
Register for Updates
Platform Clinical Study for Conquering Scleroderma
NCT06195072
Recruiting
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: University of Kansas School of Medicine, Kansas City, Kansas
Conditions: Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Register for Updates
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
NCT06205121
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Molecure Investigative Site, Kansas City, Kansas
Conditions: Pulmonary Sarcoidosis
Register for Updates
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
NCT05846646
Recruiting
Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with NSCLC or RCC
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: The University of Kansas Medical Center, Kansas City, Kansas
Conditions: Oligometastatic Disease
Register for Updates
Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240
NCT03435939
Recruiting
The goal of this study is to execute a small clinical proof of concept trial: To examine the effects of losartan on mucociliary clearance (MCC) in patients not eligible for CFTR rescue therapies
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Cystic Fibrosis
Register for Updates
A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)
NCT04192591
Recruiting
To compile real-world outcomes of the Superion™ IDS in routine clinical practice.
Gender:
All
Ages:
45 years and above
Trial Updated:
06/06/2024
Locations: University of Kansas Hospital, Kansas City, Kansas
Conditions: Lumbar Spinal Stenosis
Register for Updates